Population distribution of non-alcoholic fatty liver disease before and after renaming and risk factors for liver fibrosis in metabolic dysfunction-associated steatotic liver disease

Yan LI; Xuebing YAN; Zhonghua LU; Fang JI

doi:10.12449/JCH240611

Volume 40 Issue 6

Jun. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(6): 1136-1141

PDF( 657 KB)

Population distribution of non-alcoholic fatty liver disease before and after renaming and risk factors for liver fibrosis in metabolic dysfunction-associated steatotic liver disease

DOI: 10.12449/JCH240611

Yan LI¹,
Xuebing YAN²,
Zhonghua LU³,
Fang JI^{2
,
,
,}

1.
Graduate School of Xuzhou Medical University，Xuzhou，Jiangsu 221004，China
2.
Department of Infection and Liver Diseases，The Affiliated Hospital of Xuzhou Medical University，Xuzhou，Jiangsu 221002，China
3.
Department of Hepatology，Wuxi Fifth People’s Hospital，Wuxi，Jiangsu 214007，China

Research funding:

Natural Science Foundation of Jiangsu Province (20KJB320012)

More Information

Corresponding author: JI Fang， jifang800410@foxmail.com （ORCID： 0000-0002-9802-8890）
Received Date: 2023-08-24
Accepted Date: 2023-09-11
Published Date: 2024-06-25

Abstract

Abstract

Objective To investigate the population distribution of non-alcoholic fatty liver disease before and after renaming and the association between the types of metabolic risk factors （MRF） for metabolic dysfunction-associated steatotic liver disease （MASLD） and advanced liver fibrosis. Methods This study was conducted among 515 patients who were admitted to The Affiliated Hospital of Xuzhou Medical University and Wuxi Fifth People’s Hospital from January 2019 to January 2022 and had hepatocyte steatosis ≥5% by liver biopsy. Among these patients， 2 patients did not meet the diagnostic criteria for nonalcoholic fatty liver disease （NAFLD） and metabolic associated fatty liver disease （MAFLD）， respectively， and were classified as steatotic liver disease （SLD） with other specific causes， and the other 513 patients were divided into MASLD group with 275 patients， comorbid group with 216 patients （MASLD comorbid with other liver diseases）， and cryptogenic SLD group with 22 patients. The above groups were compared in terms of clinical features， laboratory markers， and advanced liver fibrosis. The MASLD patients with different types of MRF were compared in terms of clinical features， laboratory markers， and advanced liver fibrosis， and the risk factors for advanced liver fibrosis in patients with MASLD were analyzed. The Kruskal-Wallis H test was used for comparison of continuous data with skewed distribution between multiple groups and further comparison between two groups； the chi-square test was used for comparison of categorical data between multiple groups， and Bonferroni correction was used for further comparison between two groups. The logistic regression analysis was used to identify the risk factors for liver fibrosis. Results Among the 515 patients with SLD， 297 patients （57.7%） met the diagnostic criteria for NAFLD， among whom 22 were classified as cryptogenic SLD and 275 met the diagnostic criteria for MASLD， and 467 （90.7%） were diagnosed with MAFLD. There were significant differences between the three groups in sex， body mass index （BMI）， gamma-glutamyl transpeptidase， triglyceride， cholesterol， low-density lipoprotein cholesterol， high-density lipoprotein cholesterol， fasting plasma glucose， NAFLD fibrosis score （NFS）， fibrosis-4 （FIB-4）， and F3-4 （all P<0.05）. Compared with the MASLD group and the cryptogenic SLD group， the comorbid group had the highest proportion of patients with advanced liver fibrosis （P<0.001）. With the increase in the type of MRF， the patients tended to have an older age， a significantly higher proportion of female patients， a higher possibility of hypertension and diabetes， and higher levels of metabolic parameters including BMI， blood lipids， and blood glucose （all P<0.05）. With the increase in the types of MRF in MASLD patients， they tended to have significantly higher noninvasive fibrosis scores （NFS and FIB-4） and a significantly higher proportion of patients with advanced liver fibrosis （P<0.05）. The multivariate logistic regression analysis showed that age ≥50 years （odds ratio ［OR］=2.622， 95% confidence interval ［CI］： 1.091‍ ‍—‍ ‍6.300， P=0.031） and the increase in the type of MRF （OR=1.876， 95%CI： 1.194‍ ‍—‍ ‍2.947， P=0.006） were independent risk factors for MASLD with severe liver fibrosis. Conclusion The new definition of MASLD is based on the positive identification of MRF， and the reclassified population of MASLD is smaller than that of MAFLD， with little difference from that of NAFLD. In addition， age ≥50 years and the increase in the type of MRF are independent risk factors for MASLD with advanced liver fibrosis.
- Fatty Liver,
- Non-alcoholic Fatty Liver Disease,
- Hepatic Fibrosis

FullText(HTML)

References(23)

References

[1]	YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15( 1): 11- 20. DOI: 10.1038/nrgastro.2017.109.
[2]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73( 1): 202- 209. DOI: 10.1016/j.jhep.2020.03.039.
[3]	LIN S, HUANG JF, WANG MF, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J]. Liver Int, 2020, 40( 9): 2082- 2089. DOI: 10.1111/liv.14548.
[4]	KIM D, KONYN P, SANDHU KK, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States[J]. J Hepatol, 2021, 75( 6): 1284- 1291. DOI: 10.1016/j.jhep.2021.07.035.
[5]	NGUYEN VH, LE MH, CHEUNG RC, et al. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD[J]. Clin Gastroenterol Hepatol, 2021, 19( 10): 2172- 2181. e 6. DOI: 10.1016/j.cgh.2021.05.029.
[6]	RINELLA ME, LAZARUS JV, RATZIU V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023, 79( 6): 1542- 1556. DOI: 10.1016/j.jhep.2023.06.003.
[7]	YOUNOSSI ZM, RINELLA ME, SANYAL AJ, et al. From NAFLD to MAFLD: Implications of a premature change in terminology[J]. Hepatology, 2021, 73( 3): 1194- 1198. DOI: 10.1002/hep.31420.
[8]	LIU ST, SU KQ, ZHAO CL, et al. Research advances in medical treatment of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2021, 37( 4): 947- 950. DOI: 10.3969/j.issn.1001-5256.2021.04.048. 刘素彤, 苏凯奇, 赵晨露, 等. 代谢相关脂肪性肝病的内科治疗进展[J]. 临床肝胆病杂志, 2021, 37( 4): 947- 950. DOI: 10.3969/j.issn.1001-5256.2021.04.048.
[9]	HARRISON SA, ALLEN AM, DUBOURG J, et al. Challenges and opportunities in NASH drug development[J]. Nat Med, 2023, 29( 3): 562- 573. DOI: 10.1038/s41591-023-02242-6.
[10]	CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology[J]. Gastroenterology, 2012, 142( 7): 1592- 1609. DOI: 10.1053/j.gastro.2012.04.001.
[11]	SHEKA AC, ADEYI O, THOMPSON J, et al. Nonalcoholic steatohepatitis: A review[J]. JAMA, 2020, 323( 12): 1175- 1183. DOI: 10.1001/jama.2020.2298.
[12]	JIANG TT, SUN FF, ZENG Z, et al. Progress on metabolic associated fatty liver disease related liver cancer[J/OL]. Chin J Liver Dis(Electronic Version), 2022, 14( 3): 14- 17. DOI: 10.3969/j.issn.1674-7380.2022.03.004. 蒋婷婷, 孙芳芳, 曾湛, 等. 代谢相关脂肪性肝病相关肝癌研究进展[J/OL]. 中国肝脏病杂志(电子版), 2022, 14( 3): 14- 17. DOI: 10.3969/j.issn.1674-7380.2022.03.004.
[13]	TSOCHATZIS EA, BOSCH J, BURROUGHS AK. Liver cirrhosis[J]. Lancet, 2014, 383( 9930): 1749- 1761. DOI: 10.1016/S0140-6736(14)60121-5.
[14]	ZHAO XY, KONG YY, ZHAO XY, et al. Risk factor analysis of significant liver fibrosis in the non-obese non-alcoholic fatty liver disease patients[J]. J Clin Exp Med, 2022, 21( 14): 1497- 1500. DOI: 10.3969/j.issn.1671-4695.2022.14.011. 赵欣宇, 孔媛媛, 赵新颜, 等. 非肥胖型非酒精性脂肪性肝病显著纤维化的影响因素分析[J]. 临床和实验医学杂志, 2022, 21( 14): 1497- 1500. DOI: 10.3969/j.issn.1671-4695.2022.14.011.
[15]	HUANG SC, SU HJ, KAO JH, et al. Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease[J]. Gut Liver, 2021, 15( 3): 451- 458. DOI: 10.5009/gnl20218.
[16]	European Society for Paediatric Gastroenterology Hepatology and European Association for the Study of the Liver and European Association for the Study of the Liver(EASL) Oboca. Diagnosis of fatty liver in children should occur in parallel to investigation for other causes of liver disease[J]. Lancet Gastroenterol Hepatol, 2023, 8( 7): 598- 600. DOI: 10.1016/S2468-1253(23)00100-0.
[17]	FAN JG, YAN SY. Metabolic syndrome and fatty liver[J]. J Clin Hepatol, 2016, 32( 3): 407- 410. DOI: 10.3969/j.issn.1001-5256.2016.03.001. 范建高, 颜士岩. 代谢综合征与脂肪肝[J]. 临床肝胆病杂志, 2016, 32( 3): 407- 410. DOI: 10.3969/j.issn.1001-5256.2016.03.001.
[18]	YOUNOSSI ZM, HENRY L, BUSH H, et al. Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Clin Liver Dis, 2018, 22( 1): 1- 10. DOI: 10.1016/j.cld.2017.08.001.
[19]	GOLABI P, OTGONSUREN M, DE AVILA L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease(NAFLD)[J]. Medicine, 2018, 97( 13): e0214. DOI: 10.1097/MD.0000000000010214.
[20]	HUANG JF, OU WJ, WANG MF, et al. MAFLD criteria guide the subtyping of patients with fatty liver disease[J]. Risk Manag Healthc Policy, 2021, 14: 491- 501. DOI: 10.2147/RMHP.S285880.
[21]	FRITH J, JONES D, NEWTON JL. Chronic liver disease in an ageing population[J]. Age Ageing, 2009, 38( 1): 11- 18. DOI: 10.1093/ageing/afn242.
[22]	ADAMS LA, LYMP JF, SAUVER J ST, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study[J]. Gastroenterology, 2005, 129( 1): 113- 121. DOI: 10.1053/j.gastro.2005.04.014.
[23]	FRITH J, DAY CP, HENDERSON E, et al. Non-alcoholic fatty liver disease in older people[J]. Gerontology, 2009, 55( 6): 607- 613. DOI: 10.1159/000235677.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (66) PDF downloads(20)

Population distribution of non-alcoholic fatty liver disease before and after renaming and risk factors for liver fibrosis in metabolic dysfunction-associated steatotic liver disease

DOI: 10.12449/JCH240611

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Population distribution of non-alcoholic fatty liver disease before and after renaming and risk factors for liver fibrosis in metabolic dysfunction-associated steatotic liver disease

DOI: 10.12449/JCH240611

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content